Differential induction of LRP16 by liganded and unliganded estrogen receptor α in SKOV3 ovarian carcinoma cells

Journal of Endocrinology

Volumn 202, Issue 1, 2009, Pages 167-177

  Tian, Liyuan ^a   Wu, Zhiqiang ^a   Zhao, Yali ^a   Meng, Yuanguang ^a   Si, Yiling ^a   Fu, Xiaobing ^a   Mu, Yiming ^a   Han, Weidong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GENE PRODUCT; PROTEIN LRP16; UNCLASSIFIED DRUG; LIGAND; LRP16 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR PROTEIN;

ARTICLE; CARCINOMA CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; CARCINOMA; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETIC TRANSFECTION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING; TUMOR CELL LINE;

CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 67650738775     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-09-0054     Document Type: Article

References (57)

1. Aguiar RCT, Takeyama K, He C, Kreinbrink K & Shipp MA 2005 B-aggressive lymphoma family protein have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity. Journal of Biological Chemistry 280 33756-33765.
2. Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P & Garcia I 1997 Transgenicmice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. Journal of Clinical Investigation 99 1699-1703.
3. Auersperg N, Wong AS, Choi KC, Kang SK & Leung PC 2001 Ovarian surface epithelium: biology, endocrinology, and pathology. Endocrine Reviews 22 255-288.
4. Bai W, Oliveros-Saunders B, Wang Q, Acevedo-Duncan ME & Nicosia SV 2000 Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cellular & Developmental Biology. Animal 36 657-666.
5. Boente MP, Hurteau J, Rodriguez GC, Bast RC Jr & Berchuck A 1993 The biology of ovarian cancer. Current Opinion in Oncology 5 900-907.
6. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC & Aldaz CM 2000 Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Research 60 5977-5983.
7. Cheng JW, Yu DV, Zhou JH & Shapiro DJ 2007 Tamoxifen induction of CCAATenhancer-binding protein α is required for tamoxifen-induced apoptosis. Journal of Biological Chemistry 282 30535-30543.
8. Cheskis BJ, Greger JG, Nagpal S & Freedman LP 2007 Signaling by estrogens. Journal of Cellular Physiology 213 610-617.
9. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS & Leitman DC 2006 Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Molecular Cell 21 555-564.
10. DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A & Brown PH 2005 Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/ activator protein-1-dependent genes. Molecular Endocrinology 19 362-378.
11. Eliassen AH & Hankinson SE 2008 Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Advances in Experimental Medicine and Biology 630 148-165.
12. Foster JS, Henley DC, Ahamed S & Wimalasena J 2001 Estrogens and cell-cycle regulation in breast cancer. Trends in Endocrinology and Metabolism 12 320-327.
13. Geisinger KR, Kute TE, Pettenati MJ, Welander CE, Dennard Y, Collins LA & Berens ME 1989 Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 63 280-288.
14. Gompel A & Plu-Bureau G 2007 Ovarian cancer and hormone replacement therapy. Lancet 370 932-933.
15. Greenlee RT, Murray T, Bolden S & Wingo PA 2000 Cancer statistics. CA: A Cancer Journal for Clinicians 5 7-33.
16. Han WD, Lou FD, Yu L, Han XP, Wang QS, Li N & Zhou CX 2002 Bioinformatic analysis and subcellular distribution of LRP16 protein. Academic Journal of PLA Postgraduate Medical School 23 277-279.
17. Han WD, Mu YM, Lu XC, Xu ZM, Li XJ, Yu L, Song HJ, Li M, Lu JM, Zhao YL et al. 2003 Up-regulation of LRP16 mRNA by 17β-estradiol through activation of estrogen receptor α (ERα), but not estrogen receptor β (ERβ), and promotes human breast cancer MCF-7 cell proliferation: a preliminary report. Endocrine-Related Cancer 10 217-224.
18. Han WD, Zhao YL, Meng YG, Zang L, Wu ZQ, Li Q, Si YL, Huang K, Ba JM, Morinaga H et al. 2007 Estrogenically regulated ERα target gene LRP16 interacts with ERα and enhances the receptor's transcriptional activity. Endocrine-Related Cancer 14 741-753.
19. HanWD, Si YL, Zhao YL, Li Q, Wu ZQ, Hao HJ & Song HJ 2008 GC-rich promoter elements maximally confer estrogen-induced transactivation of LRP16 gene through ERα/Sp1 interaction in MCF-7 cells. Journal of Steroid Biochemistry and Molecular Biology 109 47-56.
20. Havrilesky LJ, McMahon CP, Lobenhofer EK, Whitaker R, Marks JR & Berchuck A 2001 Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. Journal of the Society for Gynecologic Investigation 8 104-113.
21. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujahue M, Ström A, Treuter E, Warner M et al. 2007 Estrogen receptors: how do they signal and what are their targets. Physiological Reviews 87 905-931.
22. Hong CY, Suh JH, Kim K, Gong EY, Jeon SH, Ko M, Seong RH, Kwon HB & Lee K 2005 Modulation of androgen receptor transactivation by the SWI3-related gene product (SRG3) in multiple ways. Molecular and Cellular Biology 12 4841-4152.
23. Hua W, Christianson T, Rougeot C, Rochefort H & Clinton GM 1995 SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. Journal of Steroid Biochemistry and Molecular Biology 55 279-289.
24. Langdon SP, Hawkes MM, Lawrie SS, Hawkins RA, Resdale AL, Crew AJ, Miller WR & Smyth JF 1990 Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. British Journal of Cancer 62 213-216.
25. Langdon SP, Crew AJ, Ritchie AA, Muir M, Wakeling A, Smyth JF & Miller WR 1994a Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by antiestrogens in vitro and in a xenograft model. European Journal of Cancer 30A 682-686.
26. Langdon SP, Hirst GL, Miller EP, Hawkins RA, Tesdale AL, Smyth JF & Miller WR 1994b The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. Journal of Steroid Biochemistry and Molecular Biology 50 131-135.
27. Lauritsen KJ, List HJ, Reiter R, Wellstein A & Riegel AT 2002 A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene 21 7147-7155.
28. Liao DX, Han WD, Zhao YL, Pu YD, Mu YM, Luo CH & Li XH 2006 The expression and clinical significance of LRP16 gene in human breast cancer. Ai Zheng 25 866-870.
29. McDonnell DP & Norris JD 2002 Connections and regulation of the human estrogen receptor. Science 296 1642-1644.
30. Meng YG, Han WD, Zhao YL, Huang K, Si YL, Wu ZQ & Mu YM 2007 Induction of LRP16 gene by estrogen promotes the invasive growth of Ishikawa human endometrial cancer cells through down-regulation of E-cadherin. Cell Research 17 869-880.
31. Mercier I, Colombo F, Mader S & Calderone A 2002 Ovarian hormones induce TGF-beta(3) and fibronectin mRNAs but exhibit a disparate action on cardiac fibroblast proliferation. Cardiovascular Research 53 728-739.
32. Norris JD, Fan D, Stallcup MR & McDonnell DP 1998 Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology. Journal of Biological Chemistry 273 6679-6688.
33. O'Donnell AJM, Macleod KG, Burns DJ, Smyth JF & Langdon SP 2005 Estrogen receptor-α mediates gene changes and growth response in ovarian cancer cells exposed to estrogen. Endocrine-Related Cancer 12 851-866.
34. Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, Kang K, Hadsell DL, Behrens J & Lee AV 2003 Estrogen-mediated downregulation of E-cadherin in breast cancer cells. Cancer Research 63 5203-5208.
35. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ et al. 2004 Inflammatory markers and the risk of coronary heart disease in men and women. New England Journal of Medicine 351 2599-2610.
36. Pfeilschifter J, Koditz R, Pfohl M & Schatz H 2002 Changes in proinflammatory cytokine activity after menopause. Endocrine Reviews 23 90-119.
37. Prall OW, Rogan EM, Musgrove EA, Watts CK & Sutherland RL 1998 c-Myc or Cyclin D1 mimics estrogen effects on Cyclin E-Cdk2 activation and cell cycle reentry. Molecular and Cellular Biology 18 4499-4508.
38. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E & Persson IR 2002 Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. Journal of the National Cancer Institute 94 497-504.
39. Rodrigez C, Patel AV, Calle EE, Jacob EJ & Thun MJ 2001 Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. Journal of the American Medical Association 285 1460-1465.
40. Safe S 2001 Transcriptional activation of genes by 17β-estrodial through estrogen receptor-Sp1 interactions. Vitamins and Hormones 62 231-252.
41. Sampath D, Winneker RC & Zhang Z 2001 Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human breast cancer. Endocrinology 142 2540-2548.
42. Shang YF 2006 Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nature Reviews. Cancer 6 360-368.
43. Shang Y & Brown M 2002 Molecular determinants for the tissue specifity of SERMs. Science 295 2465-2468.
44. Shi Y, Downes M, Xie W, Kao HY, Ordentlich P, Tsai CC, Hon M & Evans RM 2001 Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. Genes and Development 15 1140-1151.
45. Slotman BJ & Rao BR 1988 Ovarian cancer: etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Research 8 417-434.
46. Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, William AR, Nafussi AA, Rye T, Rye R, Stewart M et al. 2007 Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clinical Cancer Research 13 3617-3622.
47. Stossi F, Likhite VS, Katzenellenbogen JA & Katzenellenbogen BS 2006 Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter. Journal of Biological Chemistry 281 16272-16278.
48. Syed FA, Modder UIL, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL & Khosla S 2005 Skeletal effects of estrogen are mediated by opposing actions of classical and non-classical estrogen receptor pathways. Journal of Bone and Mineral Research 20 1992-2001.
49. Syed FA, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL & Khosla S 2007 Effects of loss of classical estrogen response element signaling on bone in male mice. Endocrinology 148 1902-1910.
50. Wagner U, du Bios A, Pfisterer J, Huober J, Loibl S, Lück HJ, Sehouli J, Gropp M, Stähle A, Schmalfeldt B et al. 2007 Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy - a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecologic Oncology 105 132-137.
51. Woodward TL, Mienaltowski AS, Modi RR, Bennett JM & Haslam SZ 2001 Fibronectin and the alpha(5)beta(1) integrin are under developmental and ovarian steroid regulation in the normal mouse mammary gland. Endocrinology 142 3214-3222.
52. Yager JD & Davidson NE 2006 Estrogen carcinogenesis in breast cancer. New England Journal of Medicine 354 270-282.
53. Yang J, Zhao YL, Wu ZQ, Si YL, Meng YG, Fu XB, Mu YM & Han WD 2009 The single-macro domain protein LRP16 is an essential cofactor of androgen receptor. Endocrine-Related Cancer 16 139-153.
54. Zhao YL, Han WD, Li Q, Mu YM, Lu XC, Yu L, Song HJ, Li X, Lu JM & Pan CY 2005 Mechanisms of transcripitional regulation of LRP16 gene expression by 17β-estradiol in MCF-7 human breast cancer cells. Journal of Molecular Endocrinology 34 77-89.
55. Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L & Wang B 2008 Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecologic Oncology 108 641-651.
56. Zubairy S & Oesterreich S 2005 Estrogen-repressed genes-key mediators of estrogen action? Breast Cancer Research 7 163-164.
57. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R & Michalides RJ 1997 CDK-independent activation of estrogen receptor by cyclin D1. Cell 88 405-415.